Jan 19, 2024, 13:00
Carbiotix AB ("Carbiotix" or the "Company") has drawn up an addendum (the "Addendum Memorandum") to the information memorandum published on January 16, 2024 (the "Information Memorandum").
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.
The Information Memorandum has been drawn up in connection with the ongoing rights issue of units, which was approved at an extraordinary general meeting on January 10, 2024 (the "Rights Issue"). The Addendum Memorandum has been drawn up due to the fact that Carbiotix announced on 18 January 2024 through a press release entitled "Carbiotix AB receives additional guarantee commitment in ongoing rights issue" that the Company has increased the degree of guarantees in the Company's ongoing rights issue.
Investors who, prior to the publication of the Addendum Memorandum, have made a subscription or otherwise consented to the acquisition of units in Carbiotix have the right to withdraw their notification or consent within two trading days from the publication of the document, i.e. no later than January 22, 2024. Revocation must take place to Nordic Issuing AB via email firstname.lastname@example.org. Investors who registered for the acquisition of shares through a trustee must contact their trustee regarding revocation. The subscription that has not been withdrawn will remain binding and investors who wish to remain with their subscription regarding the acquisition of units in Carbiotix do not need to take any action.
The Addendum Memorandum
The Information Memorandum and the Addendum Memorandum are available on the respective websites of the Company (www.carbiotix.com), Sedermera Corporate Finance AB (www.sedermera.se), Spotlight Stock Market (www.spotlightstockmarket.com) and Nordic Issuing AB (www.nordic-issuing.se).
In connection with the Rights Issue, Carbiotix has engaged Sedermera Corporate Finance AB as financial advisor, Markets & Corporate Law Nordic AB as legal advisor and Nordic Issuing AB as issuing agent.
For further information about the Rights Issue, please contact:
Sedermera Corporate Finance AB
Phone: +46 (0)40 615 14 10
For more information about the Company, please contact:
Erik Deaner, CEO
Phone: +46 (0)73-867 30 85
This press release does not constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants, subscription rights, BTU’s or other securities in CarbiotixAB investors should not subscribe for or acquire any securities other than on the basis of the information in the information document that will be made public before the start of the subscription period in the Rights Issue. No action has been taken and no action will be taken to permit an offer to the public in any jurisdiction other than Sweden.
public in any jurisdiction other than Sweden. This press release may not be released, published or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, South Korea, Russia, Belarus or in any other jurisdiction where the distribution of this press release would be unlawful. Nor does this press release constitute an offer to sell new shares, warrants, subscription rights, BTU’s or other securities to any person in a jurisdiction where it would not be permitted to make such an offer to such a person or where such action would require prospectus, additional registration or other measures than under Swedish law. The information document, the application form and other documents relating to the Rights Issue may not be distributed in or into any country where such distribution or the Rights Issue requires measures referred to in the previous sentence or where they would be contrary to the rules of such country. Actions contrary to this instruction may constitute a violation of applicable securities laws.
Neither shares, warrants, subscription rights, BTU’s nor any other securities have been or will be registered under the United States Securities Act of 1933 in its current wording (the "Securities Act") or the securities laws of any state or other jurisdiction in the United States and may not be offered, subscribed for, exercised, pledged, sold, resold, assigned, delivered or otherwise transferred, directly or indirectly, in or into the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any state or other jurisdiction of the United States.
This press release may contain certain forward-looking statements that reflect the Company's current views on future events and financial and operational development. Words such as "intends", " estimates", "expects", "may", "plans", "believes", " anticipates" and other expressions that imply indications or predictions of future developments or trends, and that are not based on historical facts, constitute forward-looking statements. By nature, forwardlooking statements involve known and unknown risks and uncertainties because they depend on future events and circumstances. Forward-looking statements do not constitute a guarantee of future results or developments and actual outcomes may differ materially from those expressed in forward-looking statements. Neither the Company nor anyone else undertakes to review, update, confirm or publicly announce any revisions to any forwardlooking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless required by law or the rules of Spotlight Stock Market.
Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a portfolio of prebiotic modulators and diagnostic testing services.